NASDAQ:AUPH
Aurinia Pharmaceuticals Inc Stock News
$5.21
-0.0300 (-0.573%)
At Close: May 24, 2024
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collabora
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
05:59pm, Tuesday, 15'th Dec 2020
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia”) and Lonza Ltd. (SIX: LONN) ("Lonza") today announced they have expanded their exclus
Aurinia Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
06:05am, Wednesday, 02'nd Dec 2020
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced its participation in the Piper Sandler 32nd Annual Virtual Healt
Top 10 Healthcare Stocks for the Future
06:44am, Sunday, 29'th Nov 2020
In this article we present the list of Top 10 Healthcare Stocks for the Future. Click to skip ahead and see the Top 5 Healthcare Stocks for the Future .
Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 20'th Nov 2020
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Biogen's Possible Shopping List: 3 Companies the Biotech Might Buy
10:00am, Wednesday, 11'th Nov 2020
This biotech titan should be a top player on the merger and acquisition scene next year.
Aurinia Pharmaceuticals: Q3 Earnings Insights
04:30pm, Tuesday, 10'th Nov 2020
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) fell 0.15% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 33.33% year over year to ($0.28
Aurinia Pharma's Dry Eye Study Blanks on Late-Stage Results
11:29am, Tuesday, 03'rd Nov 2020
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) shares slid on Tuesday after the company reported results from its midstage study for the treatment of dry eye syndrome (DES).
Voclosporin has proven to be a safer and much more effective derivative of cyclosporin, whose emulsion eye drop formulation was approved by FDA in 2003 to treat DES.
Recap: Aurinia Pharmaceuticals Q2 Earnings
09:29pm, Tuesday, 11'th Aug 2020
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) were unchanged after-market trading after the company reported Q2 results.Quarterly Results Earnings per share decreased 52.94% year over year to ($0.26
Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Lags Revenue Estimates
09:15pm, Tuesday, 11'th Aug 2020
Aurinia (AUPH) delivered earnings and revenue surprises of -13.04% and -53.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights
08:02pm, Tuesday, 11'th Aug 2020
AURINIA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS
Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for
04:30pm, Tuesday, 04'th Aug 2020
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
10:05am, Tuesday, 04'th Aug 2020
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at th
Aurinia Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 11, 2020
10:05am, Thursday, 30'th Jul 2020
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that it will release its second quarter 2020 financial results on Tuesday, August 11, 2020, after the markets clo
